{
  "created_at": "Fri Jul 15 3:28:0 +0000 2022",
  "id_str": "1547749266226941952",
  "full_text": "AstraZeneca-Oxford and Pfizer-BioNTech ramped up production early, and by the end of the study period had by far the most doses administered outside China https://t.co/7jSQkX5VGa",
  "display_text_range": [
    0,
    178
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/7jSQkX5VGa",
        "expanded_url": "https://econ.st/3RAMMbV",
        "display_url": "econ.st/3RAMMbV",
        "indices": [
          155,
          178
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 32,
  "favorite_count": 98,
  "possibly_sensitive": false,
  "original_created_at": "Fri Jul 15 01:05:55 +0000 2022",
  "localize": [
    {
      "locale": "ja",
      "full_text": "AstraZeneca-Oxford社とPfizer-BioNTech社は早期に生産を開始し、試験期間終了時には中国国外で投与された量が圧倒的に多くなっていました https://t.co/7jSQkX5VGa 。"
    },
    {
      "locale": "zh",
      "full_text": "阿斯利康-牛津大学和辉瑞-生物技术公司很早就开始了生产，到研究期结束时，他们是迄今为止在中国以外使用剂量最多的公司https://t.co/7jSQkX5VGa。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "阿斯利康-牛津大學和輝瑞-生物技術公司很早就開始了生產，到研究期結束時，他們是迄今爲止在中國以外使用劑量最多的公司https://t.co/7jSQkX5VGa。"
    }
  ]
}